Clinical Trial

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

Name: Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer — clinical trial record (NCT07710885)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FOENIX-BTC

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer

Trial Details

NCT Number	NCT07710885
Lead Sponsor	Taiho Pharmaceutical Co., Ltd. Collaborators: Taiho Oncology, Inc.
Conditions	Biliary Tract Cancer
Enrollment	784 participants
Start Date	2026-06-24
Primary Completion	2030-04-30 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-17